Mintz Mark, Hollenberg Emma
Mintz, MD, Hollenberg, The Center for Neurological and Neurodevelopmental Health (CNNH NeuroHealth).
Psychopharmacol Bull. 2019 Jun 20;49(2):28-40.
To examine the efficacy of lithium as a mood stabilizer for patients with autism spectrum disorder (ASD).
A retrospective chart review was performed that examined the use of both extended and immediate release lithium carbonate in patients with ASD that were treated at a single clinical center (CNNH NeuroHealth). Clinical Global Impression (CGI) scales were used to quantify baseline severity of ASD and mood symptoms as well as improvement after treatment with lithium carbonate.
Our retrospective chart review found that 73.7% (n = 14) of patients with ASD and concomitant maladaptive behaviors experienced "improvement" (CGI-I rating ≤ 3) with the addition of lithium to their treatment regimen. Those with comorbid "ADHD" phenotype were most predictive of an efficacious response (p = 0.038, Odds Ratio 12.2).
Lithium carbonate is a viable, efficacious and well tolerated alternative to various neuroleptics and other psychotropic medications for use as a mood stabilizer for patients with ASD.
研究锂盐作为自闭症谱系障碍（ASD）患者情绪稳定剂的疗效。
进行了一项回顾性病历审查，研究在单一临床中心（CNNH神经健康中心）接受治疗的ASD患者中缓释和速释碳酸锂的使用情况。临床总体印象（CGI）量表用于量化ASD和情绪症状的基线严重程度以及碳酸锂治疗后的改善情况。
我们的回顾性病历审查发现，73.7%（n = 14）患有ASD并伴有适应不良行为的患者在治疗方案中添加锂盐后经历了“改善”（CGI-I评分≤3）。伴有“注意力缺陷多动障碍”（ADHD）表型的患者最能预测有效反应（p = 0.038，优势比12.2）。
对于ASD患者，碳酸锂作为情绪稳定剂，是各种抗精神病药物和其他精神药物的一种可行、有效且耐受性良好的替代品。
